ArticleAnnals of medicine and surgery (2012)2026
Assessment of chemotherapy-associated sarcopenia using SARC-F and handgrip strength: a cross-sectional analysis.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sarcopenia is a significant health concern among patients with cancer who receive chemotherapy due to its potential impacts on treatment tolerance and functional status. Objectives: To explore the association between chemotherapeutic agents and practical sarcopenia markers, including SARC-F scores and grip strength, among oncology outpatients with advanced cancer, and to explore the relationship between chemotherapy exposure (cycle number) and functional muscle decline. Methods: A secondary analysis of a primary cross-sectional dataset of 324 patients who attended outpatient clinics at Princess Noorah Oncology Center, Jeddah. Sarcopenia was assessed via the SARC-F questionnaire and digital grip strength measurement. Associations between chemotherapeutic agents and sarcopenia markers were evaluated using inferential analyses, and agents showing significant bivariate associations were further analyzed using multiple linear regression. Results: Among chemotherapeutic agents, paclitaxel was independently associated with higher SARC-F scores ( Conclusion: Paclitaxel use is an independent predictor of functional decline in cancer patients, highlighting the need for early sarcopenia screening and tailored supportive care during taxane-based chemotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.